New and emerging combination therapies for esophageal cancer

References

• WittekindCMeyerHJÖsophagus einschließlich ösophagogastraler Übergang [Esophagus including esophagogastric junction]TNM–Klassifikation Maligner Tumoren 20107th edLeipzig, GermanySpringer-Verlag20106368
   Google Scholar
• MawhinneyMRGlasgowRECurrent treatment options for the management of esophageal cancerCancer Manag Res2012436737723152702
   PubMedGoogle Scholar
• SjoquistKMBurmeisterBHSmithersBMSurvival after neo-adjuvant chemotherapy or chemoradiotherapy for resectable esophageal carcinoma: an updated meta-analysisLancet Oncol201112768169221684205
   PubMed Web of Science ®Google Scholar
• AndoNKatoHIgakiHA randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-FU versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907)Ann Surg Oncol2012191687421879261
   PubMed Web of Science ®Google Scholar
• CunninghamDAllumWHStenningSPPerioperative chemotherapy versus surgery alone for resectable gastroesophageal cancerN Engl J Med20063551112016822992
   PubMed Web of Science ®Google Scholar
• YchouMBoigeVPignonJPPerioperative chemotherapy compared with surgery alone for resectable gastresophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trialJ Clin Oncol201129131715172121444866
   PubMed Web of Science ®Google Scholar
• Thuss-PatiencePCHofheinzRDArnoldDPerioperative chemotherapy with docetaxel, cisplatin, and capecitabine (DCX) in gastroesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)Ann Oncol201223112827283422734012
   PubMed Web of Science ®Google Scholar
• FerriLEAdesSAlcindorTPerioperative docetaxel, cisplatin, and 5-FU (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trialAnn Oncol20122361512151722039085
   PubMed Web of Science ®Google Scholar
• IdelevichEKashtanHKleinYProspective phase II study of neoadjuvant therapy with cisplatin, 5-FU, and bevacizumab for locally advanced resectable esophageal cancerOnkologie2012357–842743122846974
   PubMed Web of Science ®Google Scholar
• MacdonaldJSSmalleySRBenedettiJChemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junctionN Engl J Med20013451072573011547741
   PubMed Web of Science ®Google Scholar
• SmalleySRBenedettiJKHallerDGUpdated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resectionJ Clin Oncol201230192327233322585691
   PubMed Web of Science ®Google Scholar
• KofoedSCMuhicABaeksgaardLSurvival after adjuvant chemoradiotherapy or surgery alone in resectable adenocarcinoma at the gastroesophageal junctionScand J Surg20121011263122414465
   PubMed Web of Science ®Google Scholar
• LeichmanLPGoldmanBHBohanesPOS0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinomaJ Clin Oncol201129344555456022025151
   PubMed Web of Science ®Google Scholar
• IlsonDHMinskyBDKuGYPhase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancerCancer2012118112820282721990000
   PubMed Web of Science ®Google Scholar
• PasiniFde ManzoniGZanoniANeoadjuvant therapy with weekly docetaxel and cisplatin, 5-FU continuous infusion, and concurrent radiotherapy in patients with locally advanced esophageal cancer produced a high percentage of long-lasting pathological complete response: a phase 2 studyCancer2013119593994523165781
   PubMed Web of Science ®Google Scholar
• van HagenPHulshofMCvan LanschotJJPreoperative chemoradiotherapy for esophageal or junctional cancerN Engl J Med2012366222074208422646630
   PubMed Web of Science ®Google Scholar
• JinHLZhuHLingTSZhangHJShiRHNeoadjuvant chemoradiotherapy for resectable esophageal carcinoma: a meta-analysisWorld J Gastroenterol200915475983599120014464
   PubMed Web of Science ®Google Scholar
• NygaardKHagenSHansenHSPreoperative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of preoperative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancerWorld J Surg1992166110411091455880
   PubMed Web of Science ®Google Scholar
• ApinopCPuttisakPPreechaNA prospective study of combined therapy in esophageal cancerHepatogastroenterology19944143913937959579
   PubMedGoogle Scholar
• Le PriseEEtiennePLMeunierBA randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagusCancer1994737177917848137201
   PubMed Web of Science ®Google Scholar
• WalshTNNoonanNHollywoodDKellyAKeelingNHennessyTPA comparison of multimodal therapy and surgery for esophageal adenocarcinomaN Engl J Med199633574624678672151
   PubMed Web of Science ®Google Scholar
• BossetJFGignouxMTribouletJPChemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagusN Engl J Med199733731611679219702
   PubMed Web of Science ®Google Scholar
• UrbaSGOrringerMBTurrisiAIannettoniMForastiereAStrawdermanMRandomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinomaJ Clin Oncol200119230531311208820
   PubMed Web of Science ®Google Scholar
• LeeJLParkSIKimSBA single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinomaAnn Oncol200415694795415151953
   PubMed Web of Science ®Google Scholar
• BurmeisterBHSmithersBMGebskiVSurgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the esophagus: a randomized-controlled phase III trialLancet Oncol20056965966816129366
   PubMed Web of Science ®Google Scholar
• TepperJKrasnaMJNiedzwieckiDPhase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781J Clin Oncol20082671086109218309943
   PubMed Web of Science ®Google Scholar
• AnFSHuangJQXieYTChenSHRongTH[A prospective study of combined chemoradiotherapy followed by surgery in the treatment of esophageal carcinoma.]Zhonghua Zhong Liu Za Zhi2003254376379 Chinese. [with English abstract]12921571
   PubMedGoogle Scholar
• NatsugoeSOkumuraHMatsumotoMRandomized-controlled study on preoperative chemoradiotherapy followed by surgery versus surgery alone for esophageal squamous cell cancer in a single institutionDis Esophagus200619646847217069590
   PubMed Web of Science ®Google Scholar
• LvJCaoXFZhuBJiLTaoLWangDDLong-term efficacy of perioperative chemoradiotherapy on esophageal squamous cell carcinomaWorld J Gastroenterol201016131649165420355244
   PubMed Web of Science ®Google Scholar
• MarietteCSeitzJFMaillardESurgery alone versus chemoradiotherapy followed by surgery for localized esophageal cancer: analysis of a randomized-controlled trial FFCD 9901J Clin Oncol201028Suppl 154005
   Google Scholar
• BendellJCMeluchAPeytonJA phase II trial of preoperative concurrent chemotherapy/radiation therapy plus bevacizumab/erlotinib in the treatment of localized esophageal cancerClin Adv Hematol Oncol201210743043722895283
   PubMedGoogle Scholar
• CooperJSGuoMDHerskovicAChemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology GroupJAMA1999281171623162710235156
   PubMed Web of Science ®Google Scholar
• StahlMStuschkeMLehmannNChemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagusJ Clin Oncol200523102310231715800321
   PubMed Web of Science ®Google Scholar
• BedenneLChemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102J Clin Oncol2007251160116817401004
   PubMed Web of Science ®Google Scholar
• TeohAYChiuPWYeungWKLiuSYWongSKNgEKLong-term survival outcomes after definitive chemoradiation versus surgery in patients with resectable squamous carcinoma of the esophagus: results from a randomized-controlled trialAnn Oncol201324116517122887465
   PubMed Web of Science ®Google Scholar
• ConroyTGalaisMPRaoulJLPhase Ill randomized trial of definitive chemoradiotherapy (CRT) with FOLFOX or cisplatin and fluorouracil in esophageal cancer (EC): Final results of the PRODIGE 5/ACCORD 17 trialJ Clin Oncol201230
   Web of Science ®Google Scholar
• CrosbyTHurtCFalkSSCOPE 1:A phase 11/111 trial of chemoradiotherapy in esophageal cancer plus or minus cetuximabJ Clin Oncol201230
   Google Scholar
• ShimHJKimDEHwangJEA phase II study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin in advanced esophageal cancerCancer Chemother Pharmacol201270568369022932694
   PubMed Web of Science ®Google Scholar
• KranzfelderMSchusterTGeinitzHFriessHBüchlerPMeta-analysis of neoadjuvant treatment modalities and definitive nonsurgical therapy for esophageal squamous cell cancerBr J Surg201198676878321462364
   PubMed Web of Science ®Google Scholar
• YoonMSNamTKLeeJSVEGF as a predictor for response to definitive chemoradiotherapy and COX-2 as a prognosticator for survival in esophageal squamous cell carcinomaJ Korean Med Sci201126451352021468258
   PubMed Web of Science ®Google Scholar
• BleibergHConroyTPaillotBRandomized phase II study of cisplatin and 5-FU (5-FU) versus cisplatin alone in advanced squamous cell esophageal cancerEur J Cancer1997338121612209301445
   PubMed Web of Science ®Google Scholar
• AjaniJARodriguezWBodokyGMulticenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trialJ Clin Oncol20102891547155320159816
   PubMed Web of Science ®Google Scholar
• LeeJImYHChoEYA phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinomaCancer Chemother Pharmacol2008621778417762932
   PubMed Web of Science ®Google Scholar
• MauerAMKrautEHKraussSAPhase II trial of oxaliplatin, leucovorin, and fluorouracil in patients with advanced carcinoma of the esophagusAnn Oncol20051681320132515919687
   PubMed Web of Science ®Google Scholar
• van MeertenEEskensFAvan GamerenECFirst-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic esophageal cancer: a phase II studyBr J Cancer20079691348135217437008
   PubMed Web of Science ®Google Scholar
• JatoiAMurphyBRFosterNROxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment GroupAnn Oncol2006171293416303863
   PubMed Web of Science ®Google Scholar
• Al-BatranSEHartmannJTProbstSPhase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische OnkologieJ Clin Oncol20082691435144218349393
   PubMed Web of Science ®Google Scholar
• ZhangXShenLLiJLiYLiJJinMA phase II trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagusAm J Clin Oncol2008311293318376224
   PubMed Web of Science ®Google Scholar
• llsonDHAjaniJShallaKPhase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagusJ Clin Oncol199816182618349586897
   PubMed Web of Science ®Google Scholar
• llsonDHSaltzLEnzingerPPhase II trial of weekly irinotecan plus cisplatin in advanced esophagea l cancerJ Clin Oncol1999173270327510506629
   PubMed Web of Science ®Google Scholar
• ConroyTEtiennePLAdenisAVinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survivalAnn Oncol20021372172912075740
   PubMed Web of Science ®Google Scholar
• YunTHanJYLeeJSPhase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinomaBMC Cancer20111138521888637
   PubMed Web of Science ®Google Scholar
• GiordanoKFJatoiAStellaPJDocetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a Phase II study from the North Central Cancer Treatment GroupAnn Oncol200617465265616497828
   PubMed Web of Science ®Google Scholar
• LorenzenSDuysterJLerschCCapecitabine plus docetaxel every 3 weeks in first- and second-line metastatic esophageal cancer: final results of a phase II trialBr J Cancer200592122129213315942631
   PubMed Web of Science ®Google Scholar
• CunninghamDStarlingNRaoSCapecitabine and oxaliplatin for advanced esophagogastric cancerN Engl J Med20083581364618172173
   PubMed Web of Science ®Google Scholar
• AjaniJAFodorMBTjulandinSAPhase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinomaJ Clin Oncol200523245660566716110025
   PubMed Web of Science ®Google Scholar
• LorenzenSHentrichMHaberlCSplit-dose docetaxel, cisplatin, and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trialAnn Oncol200718101673167917660494
   PubMed Web of Science ®Google Scholar
• EvansDMinerTIannittiDDocetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer: a phase II studyCancer Invest200725644544817882656
   PubMed Web of Science ®Google Scholar
• TebbuttNCCumminsMMSourjinaTRandomized, noncomparative phase II study of weekly docetaxel with cisplatin and 5-FU or with capecitabine in esophagogastric cancer: the AGITG ATTAX trialBr J Cancer2010102347548120068567
   PubMed Web of Science ®Google Scholar
• HuangJZhouYZhangHA phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapyMed Oncol20133034323263828
   PubMed Web of Science ®Google Scholar
• ItakuraYSasanoHShigaCEpidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplificationCancer19947437958048039107
   PubMed Web of Science ®Google Scholar
• KitagawaYUedaMAndoNFurther evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinomaClin Cancer Res1996259099149816249
   PubMed Web of Science ®Google Scholar
• GibaultLMetgesJPConan-CharletVDiffuse EGFR staining is associated with reduced overall survival in locally advanced esophageal squamous cell cancerBr J Cancer200593110711515986037
   PubMed Web of Science ®Google Scholar
• WilkinsonNWBlackJDRoukhadzeEEpidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinomaJ Gastrointest Surg20048444845315120370
   PubMed Web of Science ®Google Scholar
• PintoCDi FabioFBaroneCPhase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (DOCETUX study)Br J Cancer200910181261126819773760
   PubMed Web of Science ®Google Scholar
• MoehlerMMuellerATrarbachTCetuximab with irinotecan, folinic acid, and 5-FU as first-line treatment in advanced gastroesophageal cancer: a prospective multicenter biomarker-oriented phase II studyAnn Oncol20112261358136621119032
   PubMed Web of Science ®Google Scholar
• PintoCDi FabioFSienaSPhase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)Ann Oncol200718351051717164226
   PubMed Web of Science ®Google Scholar
• LordickFLuberBLorenzenSCetuximab plus oxaliplatin/leucovorin/5-FU in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)Br J Cancer2010102350050520068568
   PubMed Web of Science ®Google Scholar
• LorenzenSSchusterTPorschenRCetuximab plus cisplatin-5-FU versus cisplatin-5-FU alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische OnkologieAnn Oncol200920101667167319549707
   PubMed Web of Science ®Google Scholar
• OkinesAFAshleySECunninghamDEpirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trialJ Clin Oncol201028253945395020679619
   PubMed Web of Science ®Google Scholar
• WaddellTSChauIBarbachanoYA randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3)J Clin Oncol201230
   Web of Science ®Google Scholar
• WainbergZALinLSDiCarloBPhase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the esophagus and gastroesophageal junctionBr J Cancer2011105676076521811258
   PubMed Web of Science ®Google Scholar
• al-KasspoolesMMooreJHOrringerMBBeerDGAmplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomasInt J Cancer19935422132198098013
   PubMed Web of Science ®Google Scholar
• RossJSMcKennaBJThe HER-2/neu oncogene in tumors of the gastrointestinal tractCancer Invest200119555456811458821
   PubMed Web of Science ®Google Scholar
• BangYJVan CutsemEFeyereislovaATrastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastroesophageal junction cancer (ToGA): a Phase 3, open-label, randomized-controlled trialLancet2010376974268769720728210
   PubMed Web of Science ®Google Scholar
• GalskyMDVon HoffDDNeubauerMTarget-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumorsInvest New Drugs201230269570120857170
   PubMed Web of Science ®Google Scholar
• InoueKOzekiYSuganumaTSugiuraYTanakaSVascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progressionCancer19977922062139010092
   PubMed Web of Science ®Google Scholar
• KitadaiYHarumaKTokutomiTSignificance of vessel count and vascular endothelial growth factor in human esophageal carcinomasClin Cancer Res199849219522009748139
   PubMed Web of Science ®Google Scholar
• KleespiesAGubaMJauchKWBrunsCJVascular endothelial growth factor in esophageal cancerJ Surg Oncol20048729510415282704
   PubMed Web of Science ®Google Scholar
• ShihCHOzawaSAndoNUedaMKitajimaMVascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagusClin Cancer Res2000631161116810741747
   PubMed Web of Science ®Google Scholar
• ShahMARamanathanRKIlsonDHMulticenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinomaJ Clin Oncol200624335201520617114652
   PubMed Web of Science ®Google Scholar
• El-RayesBFZalupskiMBekai-SaabTA phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancersAnn Oncol200921101999200420332133
   PubMed Web of Science ®Google Scholar
• KangYOhtsuAVan CutsemEAVAGAST: A randomized, double-blind, placebo controlled, phase Ill study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC)J Clin Oncol20102818s
   Web of Science ®Google Scholar
• BangYJKangYKKangWKPhase II study of sunitinib as second-line treatment for advanced gastric cancerInvest New Drugs20112961449145820461441
   PubMed Web of Science ®Google Scholar
• SunWPowellMO’DwyerPJCatalanoPAnsariRHBensonAB3rdPhase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203J Clin Oncol201028182947295120458043
   PubMed Web of Science ®Google Scholar
• KuGYIlsonDHSchwartzLHPhase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancerCancer Chemother Pharmacol200862587588018270704
   PubMed Web of Science ®Google Scholar
• AjaniJAJiangYFaustJA multicenter phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric, or gastroesophageal junction adenocarcinomaInvest New Drugs200624435335716683077
   PubMed Web of Science ®Google Scholar
• ConroyTEtiennePLAdenisAPhase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative GroupJ Clin Oncol19961411641708558192
   PubMed Web of Science ®Google Scholar
• HeathEIUrbaSMarshallJPiantadosiSForastiereAAPhase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagusInvest New Drugs2002201959912003198
   PubMed Web of Science ®Google Scholar
• MuroKHamaguchiTOhtsuAA phase II study of single-agent docetaxel in patients with metastatic esophageal cancerAnn Oncol200415695595915151954
   PubMed Web of Science ®Google Scholar
• AndersonSEO’ReillyEMKelsenDPIlsonDHPhase II trial of 96-hour paclitaxel in previously treated patients with advanced esophageal cancerCancer Invest200321451251614533440
   PubMed Web of Science ®Google Scholar
• BurkartCBokemeyerCKlumpBPereiraPTeichmannRHartmannJTA Phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancerAnticancer Res2007274C2845284817695458
   PubMed Web of Science ®Google Scholar
• FordHMarshallAWadsleyJCougar-02: A randomized phase Ill study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinomaJ Clin Oncol201230
   Google Scholar
• LordickFvon SchillingCBernhardHHennigMBredenkampRPeschelCPhase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory esophageal cancerBr J Cancer200389463063312915869
   PubMed Web of Science ®Google Scholar
• BurtnessBGibsonMEglestonBPhase II trial of docetaxel-irinotecan combination in advanced esophageal cancerAnn Oncol20092071242124819429872
   PubMed Web of Science ®Google Scholar
• ShimHJChoSHHwangJEPhase II study of docetaxel and cisplatin chemotherapy in 5-FU/cisplatin pretreated esophageal cancerAm J Clin Oncol201033662462820142726
   PubMed Web of Science ®Google Scholar
• YoshiokaTSakayoriMKatoSDose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-FU, and radiationInt J Clin Oncol200611645446017180514
   PubMedGoogle Scholar
• NakajimaYSuzukiTHarukiSA pilot trial of docetaxel and nedaplatin in cisplatin-pretreated relapsed or refractory esophageal squamous cell cancerHepatogastroenterology20085586–871631163519102357
   PubMedGoogle Scholar
• JinJXuXWangFSecond-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinomaJ Thorac Oncol2009481017102119542899
   PubMed Web of Science ®Google Scholar
• OsakaYTakagiYHoshinoSTachibanaSTsuchidaAAokiTCombination chemotherapy with docetaxel and nedaplatin for recurrent esophageal cancer in an outpatient settingDis Esophagus200619647347617069591
   PubMed Web of Science ®Google Scholar
• TanakaTFujitaHSueyoshiSSecond-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experienceChemotherapy20075344945317952006
   PubMed Web of Science ®Google Scholar
• MinamideJAoyamaNTakadaKOotaY[Evaluation of docetaxel, CDDP, and 5-FU combined therapy as second-line chemotherapy for esophagus cancer.]Gan To Kagaku Ryoho20073414952 Japanese [with English abstract]17220669
   PubMedGoogle Scholar
• ParkBBImYHHwangIGSalvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinomaInvest New Drugs200826438739218368291
   PubMed Web of Science ®Google Scholar
• ChanJABlaszkowskyLSEnzingerPCA multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinomaAnn Oncol20112261367137321217058
   PubMed Web of Science ®Google Scholar
• GoldPJGoldmanBIqbalSCetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415)J Thorac Oncol2010591472147620631636
   PubMed Web of Science ®Google Scholar
• SchoennemannKRBjerregaardJKHansenTPBiweekly cetuximab and irinotecan as second-line therapy in patients with gastroesophageal cancer previously treated with platinumGastric Cancer201114321922521409520
   PubMed Web of Science ®Google Scholar
• IlsonDHKelsenDShahMA phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagusCancer201111771409141421425140
   PubMed Web of Science ®Google Scholar
• DragovichTMcCoySFenoglio-PreiserCMPhase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127J Clin Oncol200624304922492717050876
   PubMed Web of Science ®Google Scholar
• JanmaatMLGallegos-RuizMIRodriguezJAPredictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patientsJ Clin Oncol200624101612161916575012
   PubMed Web of Science ®Google Scholar
• FerryDRAndersonMBeddardKA phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical responseClin Cancer Res200713195869587517908981
   PubMed Web of Science ®Google Scholar
• FuchsCSTomasekJChoJYREGARD: A phase Ill, randomized, double-blind ed trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing combination therapyJ Clin Oncol201230
   Google Scholar
• LawSWongJCurrent management of esophageal cancerJ Gastrointest Surg20059229131015694827
   PubMed Web of Science ®Google Scholar